Sygnature Discovery, the largest independent provider of integrated drug discovery resource and expertise in UK, has announced the next stage in its expansion plans with the addition of a new facility.
The expansion will result in the doubling of Sygnature’s drug metabolism and pharmacokinetics (DMPK) department as the company embarks on a sustained recruitment programme. Sygnature’s new facility is located at Alderley Park in Cheshire (UK). The expanded DMPK department, which focuses on the timely delivery and interpretation of discovery DMPK data to pharmaceutical and biotechnology companies through innovation, quality and commitment, will be co-located across Sygnature’s Nottingham and Alderley Park sites.
In the last two decades, DPMK become a core discipline within drug discovery, development and even post-marketing.
Sygnature Discovery launched its DMPK department in January 2015 with the appointment of Dr. Tim Schulz-Utermoehl as Director, who joined from Shire Pharmaceuticals. Since then, Dr. Schulz-Utermoehl has greatly expanded the department, recruiting specialist scientists, and added additional capabilities, most recently discovery toxicology. Sygnature’s DMPK scientists are highly-experienced with half of the department having over ten years’ experience in their field of expertise.
Headquartered in Nottingham (UK), Sygnature Discovery has core capabilities in medicinal chemistry, in vitro bioscience, computational sciences and informatics, DMPK/physical sciences and project management.